Organization
Seattle Cancer Care Alliance
5 abstracts
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.Org: University of California Irvine Medical Center, Santa Creu i Sant Pau Hospital, Seattle Cancer Care Alliance, IDIVAL, Barts Cancer Centre QMUL,
Abstract
Identification of factors to predict low risk febrile neutropenia admissions in patients with acute myeloid leukemia (AML) following intensive chemotherapy.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington Medical Center, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center,
Abstract
Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).Org: Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, Cleveland Clinic Lerner Research Institute, Cleveland, OH,
Abstract
Psychosocial health of patients engaging in medical aid in dying and their family members: A prospective descriptive analysis.Org: Texas Tech University Health Sciences Center, El Paso, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Seattle Cancer Care Alliance,
Abstract
Effect of change in ECOG performance status at diagnosis and relapse in patients with acute myeloid leukemia.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Hematology Division at University of Washington Medical Center, University of Washington Medical Center, Seattle Cancer Care Alliance,